Immunogenicity assessment in non-clinical studies

Current Opinion in Microbiology

Volumn 15, Issue 3, 2012, Pages 337-347

  Swanson, Steven J ^a   Bussiere, Jeanine ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; APOPTOSIS; BINDING AFFINITY; BIOASSAY; BIOSENSOR; CHEMOLUMINESCENCE; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; METHODOLOGY; PHAGOCYTE; PROTEIN BINDING; PURE RED CELL ANEMIA; RADIOIMMUNOPRECIPITATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; RISK ASSESSMENT; VASCULITIS;

ANIMALS; ANTIBODIES; ANTIGENS; BIOSENSING TECHNIQUES; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MODELS, IMMUNOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84864040580     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2012.05.015     Document Type: Review

References (42)

1. Subramanyam M. Immunogenicity of biotherapeutics - an overview. J Immunotoxicol 2006, 3:151-156.
2. Bhogal N. Immunotoxicity and immunogenicity of biopharmaceuticals: design concepts and safety assessment. Curr Drug Saf 2010, 5:293-307.
3. Cleland J.L., Powell M.F., Shire S.J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993, 10:307-377.
4. Kirchner H., Korfer A., Palmer P.A., Evers P., De Riese W., Knuver-Hopf J., Hadam M., Goldman U., Franks C.R., Poliwoda H., et al. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience. Mol Biother 1990, 2:145-154.
5. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2003, 18:1257-1259.
6. Singh S.K. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011, 100:354-387.
7. Lofgren J.A., Wala I., Koren E., Swanson S.J., Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods 2006, 308:101-108.
8. Patton A., Mullenix M.C., Swanson S.J., Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005, 304:189-195.
9. Barbosa M.D. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 2011, 16:345-353.
10. Gaitonde P., Balu-Iyer S.V. In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting. Methods Mol Biol 2011, 716:267-280.
11. Brinks V., Jiskoot W., Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 2011, 28:2379-2385.
12. ICH Harmonised Tripartite Guideline: preclinical safety evaluation of biotechnology derived biopharmeceuticals. 2011, S6(R1).
13. Lewis R.M., Cavagnaro J. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products. Biologicals 2010, 38:494-500.
14. Committee for medicinal products for human use. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutics Proteins; 2007.
15. Koren E., Zuckerman L.A., Mire-Sluis A.R. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002, 3:349-360.
16. Finkelman F.D., Madden K.B., Morris S.C., Holmes J.M., Boiani N., Katona I.M., Maliszewski C.R. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993, 151:1235-1244.
17. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., Kuter D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
18. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004, 289:1-16.
19. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008, 48:1267-1281.
20. Thorpe R., Swanson S.J. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol 2005, 12:28-39.
21. Hu J., Gupta S., Swanson S.J., Zhuang Y. A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum. J Immunol Methods 2009, 345:70-79.
22. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008, 333:1-9.
23. Hennes U., Jucker W., Fischer E.A., Krummenacher T., Palleroni A.V., Trown P.W., Linder-Ciccolunghi S., Rainisio M. The detection of antibodies to recombinant interferon alfa-2a in human serum. J Biol Stand 1987, 15:231-244.
24. Millett B., Sullivan A.M., Morimoto M., Parsons G. A third generation immunoassay for tumor necrosis factor alpha. Biotechniques 1994, 17:1166-1171.
25. Swanson S.J., Chirmule N. Assessing specificity for immunogenicity assays. Bioanalysis 2009, 1:611-617.
26. Lofgren J.A., Dhandapani S., Pennucci J.J., Abbott C.M., Mytych D.T., Kaliyaperumal A., Swanson S.J., Mullenix M.C. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 2007, 178:7467-7472.
27. Mimms L., Goetze A., Swanson S., Floreani M., Edwards B., Macioszek J., Okasinski G., Kiang W. Second generation assays for the detection of antibody to HBsAg using recombinant DNA-derived HBsAg. J Virol Methods 1989, 25:211-231.
28. Swanson S.J., Jacobs S.J., Mytych D., Shah C., Indelicato S.R., Bordens R.W. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Dev Biol Stand 1999, 97:135-147.
29. Jonsson U., Fagerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., Lofas S., Persson B., Roos H., Ronnberg I., et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 1991, 11:620-627.
30. Swanson S.J., Ferbas J., Mayeux P., Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004, 96:c88-c95.
31. VanCott T.C., Loomis L.D., Redfield R.R., Birx D.L. Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J Immunol Methods 1992, 146:163-176.
32. Egrie J.C., Cotes P.M., Lane J., Gaines Das R.E., Tam R.C. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods 1987, 99:235-241.
33. Garotta G., Ozmen L., Fountoulakis M., Dembic Z., van Loon A.P., Stuber D. Human interferon-gamma receptor. Mapping of epitopes recognized by neutralizing antibodies using native and recombinant receptor proteins. J Biol Chem 1990, 265:6908-6915.
34. Basser R.L., O'Flaherty E., Green M., Edmonds M., Nichol J., Menchaca D.M., Cohen B., Begley C.G. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002, 99:2599-2602.
35. Krantz S.B., Kao V. Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc Natl Acad Sci USA 1967, 58:493-500.
36. Peschle C., Marmont A.M., Marone G., Genovese A., Sasso G.F., Condorelli M. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975, 30:411-417.
37. Indelicato S.R. Bioassays for the measurement of neutralizing antibodies in serum (SNFs). Dev Biol (Basel) 2003, 112:113-125.
38. Wadhwa M., Meager A., Dilger P., Bird C., Dolman C., Das R.G., Thorpe R. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology 2000, 99:113-123.
39. Wadhwa M., Skog A.L., Bird C., Ragnhammar P., Lilljefors M., Gaines-Das R., Mellstedt H., Thorpe R. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999, 5:1353-1361.
40. Indelicato S.R., Bradshaw S.L., Chapman J.W., Weiner S.H. Evaluation of standard and state of the art analytical technology-bioassays. Dev Biol (Basel) 2005, 122:103-114.
41. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
42. Stubenrauch K., Wessels U., Essig U., Vogel R., Schleypen J. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J Pharm Biomed Anal 2010, 52:249-254.